Our writers
Our writers
The people behind Cibdol's content. Our articles are written by our authors and scientifically reviewed by Dr. Arno Hazekamp, PhD cannabis researcher, before publication.
Luke Sholl
CBD & wellness writer
Luke Sholl has been writing about cannabinoids, CBD, and the broader benefits of nature since 2011. His background includes first-hand cannabis cultivation experience spanning the full seed-to-harvest lifecycle across soil, coco, and hydroponic setups, which grounds his understanding of how cannabinoids like CBD are grown, extracted, and formulated. At Cibdol, he focuses on CBD education, product formats, and informed, safety-first use.
Adam Parsons
Journalist & copywriter
Adam Parsons is a professional CBD and wellness journalist, copywriter, and author on the Cibdol writing team. Coming from a freelance background with a BA (Hons) in Multimedia Journalism, he covers everything from CBD basics to broader wellness topics for the Cibdol wiki and blog, combining technical research skills with a clear, engaging writing style.
Joshua Askew
Editorial director
Joshua Askew directs the Cibdol editorial programme — setting editorial standards, reviewing methodology, and ensuring content quality across languages and categories. He brings years of experience leading multilingual editorial teams that produce research-grounded CBD and wellness content built to hold up to scrutiny.
Dr. Arno Hazekamp
Cannabis researcher
Dr Arno Hazekamp has been a trusted name in cannabis research since 2001. With a background in molecular biology and biopharmaceutical science, he has been an integral part of the Dutch National Medicinal Cannabis Program, focusing on quality control, product development and the design of clinical trials. He published his PhD thesis on medicinal cannabis in 2007 and presents his research at international cannabinoid research conferences. Before joining Cibdol he worked as an independent consultant with companies including Bedrocan, Storz & Bickel, Echo Pharmaceuticals, Eurofins-Proxy Labs and Axim Biotechnologies.
